Quote | Aimmune Therapeutics Inc. (NASDAQ:AIMT)
|Last Trade Date Time:||10/12/2020 04:44:59 am|
News | Aimmune Therapeutics Inc. (NASDAQ:AIMT)
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
Message Board Posts | Aimmune Therapeutics Inc. (NASDAQ:AIMT)
|znewcar1: AIMT 171% v44,6M c34.22 f65,4M||znewcar1||investorshangout||08/31/2020 8:24:24 PM|
|whytestocks: $AIMT News Article - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Ai||whytestocks||investorshangout||08/31/2020 4:15:47 PM|
|whytestocks: $AIMT News Article - (AIMT) Alert: Johnson Fistel Investigates Proposed Sale of Aimmune||whytestocks||investorshangout||08/31/2020 2:05:46 PM|
|whytestocks: $AIMT News Article - Aimmune Therapeutics Enters Definitive Agreement with Soci t s des||whytestocks||investorshangout||08/31/2020 2:00:47 PM|
|Wrong! As of March 13th the short interest||dmiller||investorshub||04/04/2020 12:54:02 PM|